RBC Capital Maintains Outperform on ADC Therapeutics, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has maintained an 'Outperform' rating on ADC Therapeutics (NYSE:ADCT), but lowered the price target from $7 to $6.
November 08, 2023 | 7:22 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ADC Therapeutics' price target has been lowered from $7 to $6 by RBC Capital, though the 'Outperform' rating is maintained.
The lowering of the price target by RBC Capital could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential in the company, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100